Open AccessAre the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review
Author(s) -
Alison Pearce,
Marion Haas,
Rosalie Viney
Publication year - 2013
Publication title -
applied health economics and health policy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.099
H-Index - 40
eISSN - 1179-1896
pISSN - 1175-5652
DOI - 10.1007/s40258-013-0058-5
Subject(s) - adverse effect , medicine , intensive care medicine , health economics , quality of life research , population , public health , pharmacology , environmental health , pathology
Antineoplastic drugs for cancer are often associated with adverse events, which influence patients' physical health, quality of life and survival. However, the modelling of adverse events in cost-effectiveness analyses of antineoplastic drugs has not been examined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom